Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The proto-oncogene SRC phosphorylates cGAS to inhibit an antitumor immune response
William Dunker, Shivam A. Zaver, Jose Mario Bello Pineda, Cameron J. Howard, Robert K. Bradley, Joshua J. Woodward
William Dunker, Shivam A. Zaver, Jose Mario Bello Pineda, Cameron J. Howard, Robert K. Bradley, Joshua J. Woodward
View: Text | PDF
Research Article Immunology Oncology

The proto-oncogene SRC phosphorylates cGAS to inhibit an antitumor immune response

  • Text
  • PDF
Abstract

Cyclic GMP-AMP synthase (cGAS) is a DNA sensor and responsible for inducing an antitumor immune response. Recent studies reveal that cGAS is frequently inhibited in cancer, and therapeutic targets to promote antitumor cGAS function remain elusive. SRC is a proto-oncogene tyrosine kinase and is expressed at elevated levels in numerous cancers. Here, we demonstrate that SRC expression in primary and metastatic bladder cancer negatively correlates with innate immune gene expression and immune cell infiltration. We determine that SRC restricts cGAS signaling in human cell lines through SRC small molecule inhibitors, depletion, and overexpression. cGAS and SRC interact in cells and in vitro, while SRC directly inhibits cGAS enzymatic activity and DNA binding in a kinase-dependent manner. SRC phosphorylates cGAS, and inhibition of cGAS Y248 phosphorylation partially reduces SRC inhibition. Collectively, our study demonstrates that cGAS antitumor signaling is hindered by the proto-oncogene SRC and describes how cancer-associated proteins can regulate the innate immune system.

Authors

William Dunker, Shivam A. Zaver, Jose Mario Bello Pineda, Cameron J. Howard, Robert K. Bradley, Joshua J. Woodward

×

Figure 3

cGAS-dependent immune responses are hindered by SRC.

Options: View larger image (or click on image) Download as PowerPoint
cGAS-dependent immune responses are hindered by SRC.
(A) Western blot of...
(A) Western blot of HEK293T cells transfected with 75 ng cGAS-pcDNA3 and 925 ng of EV, WT SRC-HA pcDNA3, or mutant SRC-HA pcDNA3 for 24 hours. (B) Coculture of L929-ISRE-LUC cells with cells in A (n = 4). (C) Coculture of L929-ISRE-LUC cells with HEK293T cells transduced with DOX-inducible SRC-targeting shRNA or treated with 30 nM dasatinib followed by ISD45 transfection for 6 hours. DOX was added for 72 hours and dasatinib for 48 hours (n = 4). (D) Western blot of A549 cGAS–KO cells. Nontarget (Scr) guide RNA and 2 independent cGAS guide RNAs are shown. cGAS expression was induced by transfecting 1 μg/mL poly(I:C) for 16 hours. (E) Coculture of L929-ISRE-LUC cells with A549 Scr and cGAS-KO cells treated with vehicle (mock) or dasatinib (30nM) for 48 hours followed by transfection with HT-DNA for 6 hours. Mock luciferase levels for each cell line was set to 1 (n = 4). Actin was used as a Western blot loading control. Statistical significance tests: Student’s t test (C and E); 1-way ANOVA with Tukey test (B). Representative luciferase and qPCR shown. n = 3 (B) and n = 2 (C and E).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts